Banque Cantonale Vaudoise Has $1.36 Million Position in IQVIA Holdings Inc. $IQV

Banque Cantonale Vaudoise reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 40.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,023 shares of the medical research company’s stock after selling 4,169 shares during the period. Banque Cantonale Vaudoise’s holdings in IQVIA were worth $1,358,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its stake in shares of IQVIA by 17.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 54,691 shares of the medical research company’s stock worth $12,328,000 after purchasing an additional 8,154 shares during the last quarter. Handelsbanken Fonder AB increased its stake in shares of IQVIA by 95.9% during the 4th quarter. Handelsbanken Fonder AB now owns 258,543 shares of the medical research company’s stock worth $58,278,000 after purchasing an additional 126,554 shares during the last quarter. Profund Advisors LLC increased its stake in shares of IQVIA by 26.2% during the 4th quarter. Profund Advisors LLC now owns 2,771 shares of the medical research company’s stock worth $625,000 after purchasing an additional 575 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of IQVIA by 7.9% during the 4th quarter. ProShare Advisors LLC now owns 34,339 shares of the medical research company’s stock worth $7,740,000 after purchasing an additional 2,510 shares during the last quarter. Finally, Gabelli Funds LLC acquired a new position in shares of IQVIA during the 4th quarter worth about $203,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQV stock opened at $167.87 on Friday. The company has a market capitalization of $28.02 billion, a price-to-earnings ratio of 20.80, a PEG ratio of 1.64 and a beta of 1.18. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The company has a 50-day simple moving average of $169.78 and a 200 day simple moving average of $197.77. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has initiated a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Truist Financial lowered their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Evercore reaffirmed an “outperform” rating and set a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, April 19th. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Finally, UBS Group reduced their target price on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $225.69.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.